Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Hypervirulent Klebsiella pneumonia (hvKP), typically linked with the hypermucoviscous phenotype, has evolved as a clinically significant pathogen responsible for catastrophic disseminated infections including osteomyelitis, pyogenic liver abscesses (PLA), and endophthalmitis in an otherwise younger and healthier population. Methods: Mansoura University Hospitals, Egypt have utilised VITEK® 2 to identify clinical K. pneumoniae isolates. The Kirby Bauer's disc diffusion method was employed to asses sensitivity to antimicrobial. String test for detecting microvasculitis, Serotyping, and Bio-typing are among the phenotypic methods employed. Polymerase chain reaction (PCR) was performed to amplify capsular serotype-specific genes (K1 and K2) as well as virulence-associated genes (rmpA and magA). Results: Over two-years, 100 hypermucoviscous phenotype K. pneumoniae and 100 classical K. pneumoniae strains were isolated and screened by string test. Hypermucoviscosity Serotyping revealed that 76 isolates had K1-type capsules, 19 had K2-type capsules, and 5 were non-K1/K2 isolates. Among the positive hypermucoviscusisolates, the prevalence of rmpA gene was 79 %, and magA gene was 40 %. Although, the prevalence of these two genes in classical Klebsiella pneumoniae (cKP) isolates was very low 11% and 7%, respectively. Aside from that, the occurrence of K capsular genes in hvKP isolates were; K1 gene 66% and K2 gene 63%.However, the occurrence of these genes in cKP isolates were limited. Conclusion: In our geographical area, hypervirulent Klebsiella pneumoniae hvKP isolates were infrequent among K. pneumoniae isolates (El-Mansoura, Egypt). This study summarized and concentrated on the epidemiology, hypervirulence-associated variables, and antibiotic resistance mechanisms of hvKP strains. This was done to let the microbiologist or clinician know that the infecting strain could be hvKP, which is more dangerous than cKP. As a result, detecting these hypervirulent strains, which harbor resistance variants, should be a top goal priority.
Hypervirulent Klebsiella pneumonia (hvKP), typically linked with the hypermucoviscous phenotype, has evolved as a clinically significant pathogen responsible for catastrophic disseminated infections including osteomyelitis, pyogenic liver abscesses (PLA), and endophthalmitis in an otherwise younger and healthier population. Methods: Mansoura University Hospitals, Egypt have utilised VITEK® 2 to identify clinical K. pneumoniae isolates. The Kirby Bauer's disc diffusion method was employed to asses sensitivity to antimicrobial. String test for detecting microvasculitis, Serotyping, and Bio-typing are among the phenotypic methods employed. Polymerase chain reaction (PCR) was performed to amplify capsular serotype-specific genes (K1 and K2) as well as virulence-associated genes (rmpA and magA). Results: Over two-years, 100 hypermucoviscous phenotype K. pneumoniae and 100 classical K. pneumoniae strains were isolated and screened by string test. Hypermucoviscosity Serotyping revealed that 76 isolates had K1-type capsules, 19 had K2-type capsules, and 5 were non-K1/K2 isolates. Among the positive hypermucoviscusisolates, the prevalence of rmpA gene was 79 %, and magA gene was 40 %. Although, the prevalence of these two genes in classical Klebsiella pneumoniae (cKP) isolates was very low 11% and 7%, respectively. Aside from that, the occurrence of K capsular genes in hvKP isolates were; K1 gene 66% and K2 gene 63%.However, the occurrence of these genes in cKP isolates were limited. Conclusion: In our geographical area, hypervirulent Klebsiella pneumoniae hvKP isolates were infrequent among K. pneumoniae isolates (El-Mansoura, Egypt). This study summarized and concentrated on the epidemiology, hypervirulence-associated variables, and antibiotic resistance mechanisms of hvKP strains. This was done to let the microbiologist or clinician know that the infecting strain could be hvKP, which is more dangerous than cKP. As a result, detecting these hypervirulent strains, which harbor resistance variants, should be a top goal priority.
Cefiderocol, also known as CFDC, is an antibiotic in the class of cephalosporins. It is from the third generation. It is effective against gram-negative bacteria. 2019 was the year that it was given US FDA approval for use in the treatment of UTIs. In recent years, there has been a dramatic rise in the prevalence of MDR due to the increased use of antibiotics. Carbapenem, which is a broad-spectrum antibiotic, is unable to treat the illness for this reason because bacteria have developed resistance to it. In this scenario, cefiderocol may be used for the therapy of this kind of infection, and it would also be of special assistance for the treatment of GNB in individuals who have few other therapeutic options available to them. For this review, studies published between 2007 and 2023 are the primary focus of the debate. This review's supporting materials were sourced via a combined search of PubMed, PubChem, and Google Scholar, including the terms "Cefiderocol," "Carbapenem," "Gram-negative Bacteria," "Carbapenem Resistance," and "Cefiderocol clinical trials" from 2007 until May 2023. The focus of this paper is the difference in mode of action of these two antibiotics and shows valid issues for carbapenem resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.